| abstract |
In the novel compounds of formula I according to the invention, G1, G2 and G3 are -CH2- or -C (O) -; m is 2 or 3; n is 0 or 1; q is 1 or 2; r is 0 or 1; Ar1 is ethylthienyl or optionally substituted phenyl, naphthyl or pyridyl; Ar 2 is optionally substituted phenyl or pyridyl; X1 and X2 are any of the symbols A), B) or C) wherein X1 in the symbol A) is hydrogen; X 2 is optionally substituted benzothiazol-2-ylcarbonyl, diphenylmethyl or diphenylhydroxymethyl in the phenyl moiety (s), or optionally substituted in the phenyl moiety and substituted with one of the nitrogen atoms, including alkyl, aralkyl, or benzimidazol-2-ylcarbonyl substituted with heteroarylalkyl, or benzimidazol-2-yl optionally substituted on phenyl and substituted with aralkyl or heteroarylalkyl on one nitrogen atom; in symbol B, X1 is hydroxy; X2 is benzothiazol-2-yl optionally substituted in the phenyl moiety, or benzimidazol-2-yl optionally substituted in the phenyl moiety and substituted with aralkyl or heteroarylalkyl on one nitrogen atom, or one optionally substituted on the phenyl moiety; an unsubstituted or optionally substituted benzimidazol-2-ylcarbonyl group; X1 and X2 in the symbol C) together represent an optionally substituted diphenylmethylidene on the phenyl groups. The compounds of the invention, their stereoisomers and pharmaceutically acceptable salt histamine receptor and tachykinin receptor antagonists. ŕ |